Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe

/in

Both companies will expand their cooperation through the distribution of medical cannabis products in the highly attractive Czech and Swiss markets Dusseldorf and Barcelona / Tel Aviv, October 6, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and Panaxia (TASE: PNAX), a global pharmaceutical company that develops, manufactures and markets advanced […]

Read more

Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors

/in

Financing led by Brandon Capital, Forbion and Atlas Venture Aims to advance its lead ADC compound targeting a novel cancer antigen Serial biotech entrepreneur Bertrand Damour appointed as Chief Executive Officer Industry veteran Leigh Zawel appointed as Chief Scientific Officer Proprietary payload platform for development of novel ADCs London UK, 28 September 2022 – Pheon Therapeutics […]

Read more

Destiny Pharma plc – Notice of R&D Update Meeting

/in

Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that it will host an R&D Update meeting for analysts and investors on Tuesday, 18 October 2022 at 1.00 pm BST / 8.00 am EST. Read more

Read more

Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer

/in

Denmark’s first fully functional generally applicable quantum computer will be available in 2034. This is the objective of the ambitious Novo Nordisk Foundation Quantum Computing Programme that is being launched in collaboration with the University of Copenhagen. Quantum computers will help in developing new medicine and provide new insight into climate change and the green […]

Read more

World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London

/in

BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial College London (ICL) to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research from world-class scientists to benefit people and society. Read more…

Read more
© Optimum Strategic Communications.